Lista de obras - Jérôme Giustiniani - Dominio Público Uruguay

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor ⬇️

artículo científico publicado en 2011

A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity

artículo científico publicado en 2007

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models

artículo científico publicado en 2018

Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.

artículo científico publicado en 2015

CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases

artículo científico publicado en 2018

CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.

artículo científico publicado en 2010

CD160: a unique activating NK cell receptor

scientific article published on 13 February 2011

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.

artículo científico publicado en 2017

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

artículo científico publicado en 2017

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

artículo científico publicado en 2017

Differential and tumor-specific expression of CD160 in B-cell malignancies ⬇️

artículo científico publicado el 28 de junio de 2011

Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.

artículo científico publicado en 2002

Engagement of IL-1 receptor accessory protein (IL-1RAcP) with the monoclonal antibody AY19 provides co-activating signals and prolongs the CD2-induced proliferation of peripheral blood lymphocytes.

artículo científico publicado en 2011

Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.

artículo científico publicado en 2010

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells

artículo científico publicado en 2015

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

artículo científico publicado en 2013

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells

scientific article published on 23 July 2016

Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes

artículo científico publicado en 2016

Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation

artículo científico publicado en 2007

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity

artículo científico publicado en 2014

Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome

artículo científico publicado en 2015

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.

artículo científico publicado en 2015

Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

artículo científico publicado en 2017

Possible Pathogenic Role of the Transmembrane Isoform of CD160 NK Lymphocyte Receptor in Paroxysmal Nocturnal Hemoglobinuria ⬇️

artículo científico publicado el 1 de febrero de 2012

Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells

artículo científico publicado en 2006

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type

artículo científico publicado en 2016

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

artículo científico publicado en 2017

The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function

artículo científico publicado en 2006

[A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor]

scientific article published on 27 January 2012

Lista de obras de Jérôme Giustiniani

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor ⬇️

A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models

Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.

CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases

CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.

CD160: a unique activating NK cell receptor

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Differential and tumor-specific expression of CD160 in B-cell malignancies ⬇️

Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.

Engagement of IL-1 receptor accessory protein (IL-1RAcP) with the monoclonal antibody AY19 provides co-activating signals and prolongs the CD2-induced proliferation of peripheral blood lymphocytes.

Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells

Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes

Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity

Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.

Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Possible Pathogenic Role of the Transmembrane Isoform of CD160 NK Lymphocyte Receptor in Paroxysmal Nocturnal Hemoglobinuria ⬇️

Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function

[A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor]